Search | Clinical Trials Finder

Conditions: Corneal Disease, Fuch's Dystrophy, Pseudophakic Corneal Edema
Interventions: corneas assigned by donor age group; Other
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: 40 Years to 80 Years
Enrollment: 1,090 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2014
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Corneal Transplantation
Interventions: Optical coherence tomography (OCT); Device
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Timeline: 2027 – 2030
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Fuchs Endothelial Corneal Dystrophy, Corneal Endothelial Decompensation
Interventions: Descemet membrane endothelial keratoplasty; Procedure
Lead sponsor: Case Western Reserve University; Other
Eligibility: 30 Years to 93 Years
Enrollment: 570 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 14
States / cities: Atlanta, Georgia • Indianapolis, Indiana • Iowa City, Iowa + 10 more

Conditions: Corneal Endothelial Dystrophy, Corneal Edema
Interventions: loteprednol etabonate 0.25% ophthalmic suspension; Drug
Lead sponsor: Price Vision Group; Industry
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Keratoconus
Interventions: Riboflavin 5'-phosphate in 20% dextran ophthalmic solution) 0.146% with UV light, Riboflavin 5'-phosphate in 20% dextran ophthalmic solution) 0.146% without UV light; Drug
Lead sponsor: Joseph B. Ciolino, MD; Other
Eligibility: 18 Years to 50 Years
Enrollment: 216 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hyperopia
Interventions: Optimal Keratoplasty; Device
Lead sponsor: NTK Enterprises, Inc.; Industry
Eligibility: 40 Years and older
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2018
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Fuchs Endothelial Corneal Dystrophy, Fuchs
Interventions: DT-168; Drug
Lead sponsor: Design Therapeutics, Inc.; Industry
Eligibility: 30 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 2
States / cities: Indianapolis, Indiana • Grand Rapids, Michigan

Conditions: Complications of Corneal Transplant
Interventions: Corneal donor storage in Optisol GS media solution, Life 4°C solution for cornea storage; Other
Lead sponsor: University Hospitals Cleveland Medical Center; Other
Eligibility: 30 Years to 85 Years
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 4
States / cities: Indianapolis, Indiana • Grand Rapids, Michigan • Cleveland, Ohio + 1 more

Conditions: Fuchs' Endothelial Dystrophy
Interventions: Netarsudil Ophthalmic; Drug
Lead sponsor: Massachusetts Eye and Ear Infirmary; Other
Eligibility: 40 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Fuchs' Endothelial Dystrophy
Interventions: DSAEK with graft shaping and smoothing, Standard DSAEK; Procedure
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Fuchs' Endothelial Dystrophy
Interventions: Ripasudil hydrochloride hydrate 0.4% ophthalmic solution; Drug
Lead sponsor: Marian Macsai, MD; Other
Eligibility: 18 Years to 91 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Glenview, Illinois

Conditions: Corneal Diseases, Cornea Transplant
Interventions: LX201, Placebo; Drug · Other
Lead sponsor: Lux Biosciences, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 368 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 24
States / cities: Phoenix, Arizona • Loma Linda, California • Los Angeles, California + 19 more

Conditions: Transplant, Intraocular Pressure
Interventions: anecortave acetate, 30 mg anecortave acetate; Drug
Lead sponsor: Cornea Research Foundation of America; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Corneal Transplant, Corneal Crosslinking, Healthy Eyes
Interventions: BOSS Imaging; Diagnostic Test
Lead sponsor: Intelon Optics, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Fayetteville, Arkansas

Conditions: Keratoconus and Post-keratoplasty
Interventions: Not listed
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years to 100 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Anterior Chamber Inflammation, Ocular Pain, Corneal Edema, Corneal Defect, Penetrating KeratoPlasty, Nuclear Cataract, Cortical Cataract, Cataract Senile
Interventions: Dextenza 0.4Mg Ophthalmic Insert; Drug
Lead sponsor: Nicole Fram M.D.; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Corneal Transplantation
Interventions: Deep Lamellar Endothelial Keratoplasty: Small Incision Technique; Procedure
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 21 Years to 95 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Corneal Neovascularization, Corneal Graft Failure
Interventions: Avastin® (bevacizumab), 0.9% NaCl & Refresh Liquigel; Drug
Lead sponsor: Reza Dana, MD; Other
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 3
States / cities: Miami, Florida • Boston, Massachusetts • New York, New York

Conditions: Corneal Edema, Corneal Endothelial Dysfunction, Fuchs Endothelial Corneal Dysfunction, Pseudophakic Bullous Keratopathy (PBK)
Interventions: Combination Product: AURN001 + Y-27632, Placebo; Drug · Other
Lead sponsor: Aurion Biotech; Industry
Eligibility: 18 Years and older
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 12
States / cities: Mesa, Arizona • Little Rock, Arkansas • Fort Collins, Colorado + 9 more

Conditions: Corneal Transplantation
Interventions: EndoSaver™ Corneal Endothelium Delivery Instrument; Device
Lead sponsor: Ocular Systems, Inc.; Industry
Eligibility: 45 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Corneal Transplantation, Corneal Graft Rejection
Interventions: LX201, Placebo; Drug · Other
Lead sponsor: Lux Biosciences, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 122 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 24
States / cities: Phoenix, Arizona • Loma Linda, California • Los Angeles, California + 19 more

Conditions: Corneal Endothelial Decompensation, Fuchs' Endothelial Dystrophy
Interventions: Descemet membrane endothelial keratoplasty; Procedure
Lead sponsor: Case Western Reserve University; Other
Eligibility: 30 Years to 90 Years
Enrollment: 1,097 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 2
States / cities: Indianapolis, Indiana • Grand Rapids, Michigan

Conditions: Corneal Transplant Failure
Interventions: Corneal Donor Tissue with Cross Linking, Corneal Donor Tissue without Cross Linking; Procedure
Lead sponsor: Massachusetts Eye and Ear Infirmary; Other
Eligibility: 18 Years and older
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 12
States / cities: Irvine, California • Los Angeles, California • San Francisco, California + 9 more

Conditions: Penetrating Keratoplasty, Multiple Graft Failure, Ocular Cicatricial Pemphigoid, Stevens-Johnson Syndrome
Interventions: Adalimumab Injection; Drug
Lead sponsor: Massachusetts Eye and Ear Infirmary; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Search by objective public record fields.

Cornea Donor Study

Intraoperative Optical Coherence Tomography for Ophthalmic Surgical Guidance - Cornea

Effect of Donor Diabetes and Other Factors on Corneal Transplant Endothelial Cell Loss and Success at 5 Years

Loteprednol Etabonate 0.25% for Prevention of Cornea Transplant Rejection

A Randomized Clinical Trial of Ex Vivo Corneal Cross-Linking of Donor Keratoplasty Tissue for Keratoconus Used for Keratoplasty in Keratoconus Patients

Hyperopia Correction Using the NTK Optimal Keratoplasty (Opti-K) System

DT-168 in Keratoplasty Patients With Fuchs Endothelial Corneal Dystrophy

Life 4°C Versus Optisol in Corneal Storage Media

Netarsudil Use After Descemtorhexis Without Endothelial Keratoplasty

OCT-guided DSAEK Graft Shaping and Smoothing

Glanatec(R) for Descemet Stripping in Fuch's Endothelial Dystrophy

Study to Assess the Efficacy and Safety of LX201 for Prevention of Corneal Allograft Rejection Episodes and Graft Failure in Subjects at Increased Immunological Risk

Anecortave Acetate Injection to Treat Steroid-responsive Intraocular Pressure Increase in Cornea Transplant Patients

A Prospective Clinical Trial Designed to Evaluate the Repeatability and Reproducibility of the Intelon BOSS(tm) System

Observational Study of Keratoconus and Post-keratoplasty Eyes

A Retrospective Review of DEXTENZA 0.4 mg inseRt Following Corneal Transplant or Cataract Surgery

Deep Lamellar Endothelial Keratoplasty: Small Incision Technique

A Multi-Center Study of the Safety and Efficacy of Bevacizumab in High-Risk Corneal Transplant Survival

AURN001 Efficacy in Participants With Corneal Edema Secondary to Corneal Endothelial Dysfunction

Corneal Endothelium Delivery Instrument

Study to Assess LX201 for Prevention of Corneal Allograft Rejection or Graft Failure in Subjects Who Have Experienced One or More Rejection Episodes Following Penetrating Keratoplasty

Impact of Donor Diabetes on DMEK Success and Endothelial Cell Loss

ExCrossV Multi Site Trial for Vascularized High Risk Keratoplasty

Subconjunctival Humira for Boston Keratoprosthesis